PL3740492T3 - Związki 1,2,3’,5’‐tetrahydro‐2’H‐spiro[indolo‐3,1’‐pirolo[3,4‐c]pirolo]‐2,3’‐dionowe jako środki terapeutyczne aktywujące TP53 - Google Patents

Związki 1,2,3’,5’‐tetrahydro‐2’H‐spiro[indolo‐3,1’‐pirolo[3,4‐c]pirolo]‐2,3’‐dionowe jako środki terapeutyczne aktywujące TP53

Info

Publication number: PL3740492T3
Authority: PL; Poland
Prior art keywords: pyrrolo; spiro; indole; pyrrole; tetrahydro
Prior art date: 2018-01-16

Application number

PL19701777.5T

Other languages

English (en)

Inventor

Marcin FEDER

Maria Mazur

Iwona KALINOWSKA

Joanna JASZCZEWSKA-ADAMCZAK

Wojciech LEWANDOWSKI

Jakub WITKOWSKI

Sabina Jeleń

Katarzyna Woś-Latosi

Original Assignee

Adamed Pharma S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-01-16

Filing date

2019-01-09

Publication date

2022-08-08

2019-01-09 Application filed by Adamed Pharma S.A. filed Critical Adamed Pharma S.A.

2022-08-08 Publication of PL3740492T3 publication Critical patent/PL3740492T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL19701777.5T 2018-01-16 2019-01-09 Związki 1,2,3’,5’‐tetrahydro‐2’H‐spiro[indolo‐3,1’‐pirolo[3,4‐c]pirolo]‐2,3’‐dionowe jako środki terapeutyczne aktywujące TP53 PL3740492T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP18461506.0A EP3511334A1 (en)	2018-01-16	2018-01-16	1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
PCT/EP2019/050370 WO2019141549A1 (en)	2018-01-16	2019-01-09	1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53

Publications (1)

Publication Number	Publication Date
PL3740492T3 true PL3740492T3 (pl)	2022-08-08

Family

ID=60997409

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL19701777.5T PL3740492T3 (pl)	2018-01-16	2019-01-09	Związki 1,2,3’,5’‐tetrahydro‐2’H‐spiro[indolo‐3,1’‐pirolo[3,4‐c]pirolo]‐2,3’‐dionowe jako środki terapeutyczne aktywujące TP53

Country Status (24)

Country	Link
US (1)	US12415811B2 (pl)
EP (2)	EP3511334A1 (pl)
JP (1)	JP7284190B2 (pl)
KR (1)	KR102755407B1 (pl)
CN (1)	CN111566110B (pl)
AU (1)	AU2019209114B2 (pl)
CY (1)	CY1125134T1 (pl)
DK (1)	DK3740492T3 (pl)
EA (1)	EA202091718A1 (pl)
ES (1)	ES2911229T3 (pl)
HR (1)	HRP20220458T1 (pl)
HU (1)	HUE058461T2 (pl)
IL (1)	IL276006B2 (pl)
LT (1)	LT3740492T (pl)
MX (1)	MX2020007580A (pl)
PL (1)	PL3740492T3 (pl)
PT (1)	PT3740492T (pl)
RS (1)	RS63123B1 (pl)
SG (1)	SG11202006048PA (pl)
SI (1)	SI3740492T1 (pl)
SM (1)	SMT202200172T1 (pl)
UA (1)	UA127457C2 (pl)
WO (1)	WO2019141549A1 (pl)
ZA (1)	ZA202004972B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN119613416B (zh) *	2024-12-23	2025-11-04	聊城金歌合成材料有限公司	甲氧基螺吲哚吡咯烷酮化合物的合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070213341A1 (en) *	2006-03-13	2007-09-13	Li Chen	Spiroindolinone derivatives
US7834179B2 (en) *	2007-05-23	2010-11-16	Hoffmann-La Roche Inc.	Spiroindolinone derivatives
US7776875B2 (en) *	2007-12-19	2010-08-17	Hoffman-La Roche Inc.	Spiroindolinone derivatives
US7723372B2 (en)	2008-03-19	2010-05-25	Hoffman-La Roche Inc.	Spiroindolinone derivatives
US8076482B2 (en) *	2009-04-23	2011-12-13	Hoffmann-La Roche Inc.	3,3′-spiroindolinone derivatives
US8088815B2 (en) *	2009-12-02	2012-01-03	Hoffman-La Roche Inc.	Spiroindolinone pyrrolidines
US8217044B2 (en) *	2010-04-28	2012-07-10	Hoffmann-La Roche Inc.	Spiroindolinone pyrrolidines
US20120071499A1 (en) *	2010-09-20	2012-03-22	Xin-Jie Chu	Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
JP2014500870A (ja) *	2010-11-12	2014-01-16	ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン	スピロ−オキシインドールｍｄｍ２アンタゴニスト
SG193002A1 (en) *	2011-03-10	2013-09-30	Daiichi Sankyo Co Ltd	Dispiropyrrolidine derivative
WO2012155066A2 (en)	2011-05-11	2012-11-15	Shaomeng Wang	Spiro-oxindole mdm2 antagonists
WO2013080141A1 (en)	2011-11-29	2013-06-06	Novartis Ag	Pyrazolopyrrolidine compounds
UY34591A (es) *	2012-01-26	2013-09-02	Novartis Ag	Compuestos de imidazopirrolidinona
CA2945527C (en) *	2014-04-17	2022-05-17	The Regents Of The University Of Michigan	Mdm2 inhibitors and therapeutic methods using the same
WO2015189799A1 (en)	2014-06-12	2015-12-17	Adamed Sp. Z O.O.	Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction
WO2016001376A1 (en) *	2014-07-03	2016-01-07	Boehringer Ingelheim International Gmbh	New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CA2958193C (en) *	2014-08-18	2024-02-27	Hudson Biopharma Inc.	Spiropyrrolidines as mdm2 inhibitors
RS59111B1 (sr) *	2014-08-21	2019-09-30	Boehringer Ingelheim Int	Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori
KR20240158360A (ko) *	2015-10-09	2024-11-04	베링거 인겔하임 인터내셔날 게엠베하	Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
CN105585570B (zh) *	2015-12-15	2019-10-15	贵州大学	异恶唑拼接吡咯螺环氧化吲哚化合物及其制备方法及应用
CN105669683B (zh) *	2015-12-28	2020-06-16	徐州医学院	一类吲哚螺吡咯衍生物的合成及其作为肿瘤治疗药物的应用
CN106008532B (zh) *	2016-07-20	2019-06-07	贵州大学	烷氧基嘧啶拼接3-吡咯螺环氧化吲哚衍生物及其制备方法及应用

2018
- 2018-01-16 EP EP18461506.0A patent/EP3511334A1/en not_active Withdrawn
2019
- 2019-01-09 EP EP19701777.5A patent/EP3740492B1/en active Active
- 2019-01-09 EA EA202091718A patent/EA202091718A1/ru unknown
- 2019-01-09 UA UAA202004497A patent/UA127457C2/uk unknown
- 2019-01-09 JP JP2020559015A patent/JP7284190B2/ja active Active
- 2019-01-09 AU AU2019209114A patent/AU2019209114B2/en active Active
- 2019-01-09 DK DK19701777.5T patent/DK3740492T3/da active
- 2019-01-09 SM SM20220172T patent/SMT202200172T1/it unknown
- 2019-01-09 MX MX2020007580A patent/MX2020007580A/es unknown
- 2019-01-09 PL PL19701777.5T patent/PL3740492T3/pl unknown
- 2019-01-09 RS RS20220326A patent/RS63123B1/sr unknown
- 2019-01-09 HU HUE19701777A patent/HUE058461T2/hu unknown
- 2019-01-09 SI SI201930201T patent/SI3740492T1/sl unknown
- 2019-01-09 KR KR1020207020046A patent/KR102755407B1/ko active Active
- 2019-01-09 WO PCT/EP2019/050370 patent/WO2019141549A1/en not_active Ceased
- 2019-01-09 US US16/962,647 patent/US12415811B2/en active Active
- 2019-01-09 LT LTEPPCT/EP2019/050370T patent/LT3740492T/lt unknown
- 2019-01-09 SG SG11202006048PA patent/SG11202006048PA/en unknown
- 2019-01-09 PT PT197017775T patent/PT3740492T/pt unknown
- 2019-01-09 HR HRP20220458TT patent/HRP20220458T1/hr unknown
- 2019-01-09 CN CN201980007138.5A patent/CN111566110B/zh active Active
- 2019-01-09 ES ES19701777T patent/ES2911229T3/es active Active
2020
- 2020-07-13 IL IL276006A patent/IL276006B2/en unknown
- 2020-08-12 ZA ZA2020/04972A patent/ZA202004972B/en unknown
2022
- 2022-04-05 CY CY20221100257T patent/CY1125134T1/el unknown

Also Published As

Publication number	Publication date
SG11202006048PA (en)	2020-08-28
BR112020014427A2 (pt)	2020-12-01
CY1125134T1 (el)	2024-02-16
NZ765577A (en)	2024-10-25
CA3086440A1 (en)	2019-07-25
AU2019209114B2 (en)	2022-12-08
EP3740492B1 (en)	2022-03-02
UA127457C2 (uk)	2023-08-30
MX2020007580A (es)	2020-11-18
SI3740492T1 (sl)	2022-05-31
KR102755407B1 (ko)	2025-01-20
EA202091718A1 (ru)	2020-10-27
WO2019141549A9 (en)	2019-10-10
AU2019209114A1 (en)	2020-07-09
RS63123B1 (sr)	2022-05-31
SMT202200172T1 (it)	2022-05-12
CN111566110B (zh)	2023-04-25
JP7284190B2 (ja)	2023-05-30
WO2019141549A1 (en)	2019-07-25
US20200354372A1 (en)	2020-11-12
IL276006B2 (en)	2023-03-01
US12415811B2 (en)	2025-09-16
EP3740492A1 (en)	2020-11-25
JP2021512141A (ja)	2021-05-13
HRP20220458T1 (hr)	2022-05-27
IL276006B (en)	2022-11-01
PT3740492T (pt)	2022-04-13
KR20200110322A (ko)	2020-09-23
LT3740492T (lt)	2022-05-10
HUE058461T2 (hu)	2023-09-28
DK3740492T3 (da)	2022-04-19
ZA202004972B (en)	2021-08-25
EP3511334A1 (en)	2019-07-17
CN111566110A (zh)	2020-08-21
IL276006A (en)	2020-08-31
ES2911229T3 (es)	2022-05-18

Publication	Publication Date	Title
DOP2018000263A (es)	2019-03-31	Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4
IL281719B (en)	2022-06-01	4'-phenyl-2-oxospiro]indoline-3,3'-pyrrolidine]-5' carboxamide derivatives as mdm2 protein complexes
AR110368A1 (es)	2019-03-20	Inhibidores de la rip1 cinasa y métodos y uso de éstos
NZ751509A (en)	2023-03-31	Combination therapy with 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
IL280513A (en)	2021-03-01	Imidazo[2,1-B]pyridazines as TRK inhibitors
HUE067545T2 (hu)	2024-11-28	Pirrolo[l,2-B] piridazin-származékok
AR112788A1 (es)	2019-12-11	Compuesto pentacíclico
CL2009001158A1 (es)	2009-10-23	Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer.
PL3740492T3 (pl)	2022-08-08	Związki 1,2,3’,5’‐tetrahydro‐2’H‐spiro[indolo‐3,1’‐pirolo[3,4‐c]pirolo]‐2,3’‐dionowe jako środki terapeutyczne aktywujące TP53
ZA202100158B (en)	2023-06-28	Imidazo[1,2-b]pyridazine derivatives as trk inhibitors
FI3770162T3 (fi)	2023-06-02	Dihydrokromeenijohdannainen
PH12016502271A1 (en)	2017-02-06	Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
WO2014193881A8 (en)	2016-04-07	Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
WO2015145333A8 (en)	2015-11-26	Process for the preparation of sitagliptin and its intermediate